Medtronic’s recent FDA-approved Aurora Extravascular Implantable Cardioverter Defibrillator (EV-ICD) is poised to revolutionise the cardiac device market. This device, which places leads outside both ...

The U.S. Food and Drug Administration (FDA) recently granted marketing approval for Boston Scientific Corporation 's BSX Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System, in line with ...

Boston Scientific CorporationBSX has commenced a global, multi-center UNTOUCHED trial to evaluate the clinical efficiency of its Emblem Subcutaneous Implantable Defibrillator (S-ICD) System. This move ...

Boston Scientific is recalling the Emblem S-ICD Subcutaneous Electrode because of increased risk of fractures at a specific point (distal to the proximal sense ring), FDA reported this week. The ...

Boston Scientific got FDA approval for the S-ICD implant.--Courtesy of Boston Scientific What does $150 million get you these days? For Boston Scientific ($BSX), its ...

Boston Scientific's S-ICD posted fewer lead complications than traditional implants in a new study.--Courtesy of Boston Scientific Boston Scientific's ($BSX) S-ICD ...

Boston Scientific's Emblem S-ICD, the next generation subcutaneous ICD product, is a novel technology that removes what many believe is the weakest link in implantable cardioverter defibrillators - ...

For the last year, Boston Scientific’s (NYSE:BSX) stock has hovered between $5 and $6, and no amount of share buybacks have nudged the price up much. In the company’s second-quarter earnings call last ...